neoHIP
neoHIP: Phase II Trial of Neoadjuvant Pembrolizumab + HER2-Targeted Therapy for HER2-Positive Early Breast Cancer

Released: December 17, 2024

Expiration: June 16, 2025

Activity

Progress
1
Course Completed